Eikon Therapeutics, based in Hayward, Calif., was founded in 2019 by Eric Betzig, Xavier Darzacq, Luke Lavis, and Robert Tjian. In 2014, Betzig shared the Nobel Prize in Chemistry. Robert Perlmutter is the company’s chairman and CEO. Eikon, which was last valued on January 2022 at $3.1 billion, is a drug discovery and development company that leverages superior engineering and high-performance computing to analyze single molecule protein behavior in living cells.
In January 2022, the company raised $525 million in Series B financing led by more than a dozen investors including T. Rowe Price Associates, Inc., Canada Pension Plan Investment Board, UC Investments, Soros Capital and Schroders Capital.
These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
05/16/2023 | Series C | $535MM | $xx.xx | $4.74B | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
24,884,830
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Undisclosed Investors
|
||||||
01/06/2022 | Series B | $525MM | $xx.xx | $3.1B | T. Rowe Price Associates, Inc., Canada Pension Plan Investment Board, EcoR1 Capital, UC Investments, ADIA, StepStone Group, Soros Capital, Schroders Capital, Harel Insurance, General Catalyst, E15 VC, Hartford HealthCare Endowment, AME Cloud Ventures, The Column Group, Foresite Capital, Innovaction Endeavors, Lux Capital, Horizon Ventures | |
Price per Share
$xx.xx
Shares Outstanding
29,680,164
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
T. Rowe Price Associates, Inc., Canada Pension Plan Investment Board, EcoR1 Capital, UC Investments, ADIA, StepStone Group, Soros Capital, Schroders Capital, Harel Insurance, General Catalyst, E15 VC, Hartford HealthCare Endowment, AME Cloud Ventures, The Column Group, Foresite Capital, Innovaction Endeavors, Lux Capital, Horizon Ventures
|
||||||
05/05/2021 | Series A-1 | $102.54MM | $xx.xx | $248.17MM | The Column Group, Foresite Capital, Innovation Endeavors, Lux Capital | |
Price per Share
$xx.xx
Shares Outstanding
51,268,891
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
The Column Group, Foresite Capital, Innovation Endeavors, Lux Capital
|
||||||
05/05/2021 | Series A | $48MM | $xx.xx | $248.17MM | The Column Group, Foresite Capital, Innovation Endeavors, Lux Capital | |
Price per Share
$xx.xx
Shares Outstanding
48,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
The Column Group, Foresite Capital, Innovation Endeavors, Lux Capital
|